ATAI Life Sciences Acquires Majority Stake in Kures

Atairos Acquires LifeLabs Learning

March 24, 2023

Education

Atairos, an independent strategic investment company, acquired LifeLabs Learning, a provider of manager and team upskilling programs, in a transaction that closed on March 23, 2023. The investment will accelerate LifeLabs Learning’s rollout of digital learning innovations and support growth of its manager-focused training programs; Houlihan Lokey served as exclusive financial advisor to Atairos.

PharmaForceIQ Acquires Aktana

January 9, 2026

Cloud & SaaS

PharmaForceIQ has acquired Aktana in an asset acquisition to integrate Aktana's AI-driven field Next-Best-Action platform into PharmaForceIQ's digital orchestration offering. The deal is intended to create an end-to-end 'optichannel-in-a-box' commercial engagement solution for life sciences, deepen PharmaForceIQ's U.S. footprint and expand reach across LATAM, APAC and EMEA; Canaccord Genuity acted as sole financial advisor.

Petauri Health (Oak Hill) Acquires The Kinetix Group

June 13, 2023

Healthcare Services

Petauri Health, a pharmaceutical commercialization platform formed by Oak Hill Capital, has acquired The Kinetix Group (TKG), a New York–based market access, access marketing, and medical affairs agency. The Kinetix founders will remain in leadership roles as TKG becomes the inaugural add-on to the Petauri platform, expanding the platform's market access, medical affairs, and real-world evidence capabilities.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.

TuHURA Biosciences Acquires Kineta

June 30, 2025

Biotechnology

TuHURA Biosciences (Nasdaq: HURA) completed the acquisition of Kineta, Inc., adding Kineta's Phase 2-ready VISTA inhibiting monoclonal antibody (now TBS-2025) to TuHURA's immuno-oncology pipeline. The deal was structured as a stock-for-stock merger and will enable TuHURA to initiate a Phase 2 trial and unlock further PIPE financing tranches tied to the transaction.

Anblicks Acquires Krya Insights

June 5, 2024

Data & Analytics

Anblicks, a Dallas-based technology consulting firm, has acquired Krya Insights, a specialist data & AI firm focused on retail analytics. As part of the transaction, Krya Insights' founder Kumar Raman will join Anblicks as Chief Product & Technology Officer to help expand the company's data, analytics and AI capabilities.